| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Trea | Phase III | rekrutiert |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Trea | Phase III | rekrutiert |
| A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor f | — | rekrutiert |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab a | Phase III | rekrutiert |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Ch | Phase III | rekrutiert |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adju | Phase III | rekrutiert |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early | Phase III | rekrutiert |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelod | Phase II | rekrutiert |
| A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) | Phase III | rekrutiert |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembroliz | Phase III | rekrutiert |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated | Phase II / Phase III | rekrutiert |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan ( | Phase III | rekrutiert |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab P | Phase III | rekrutiert |
| AXillary Surgery After NeoAdjuvant Treatment | — | rekrutiert |
| BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatmen | — | rekrutiert |
| Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected St | Phase III | rekrutiert |
| Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Ad | Phase III | rekrutiert |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase III | rekrutiert |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD | Phase III | rekrutiert |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Re | Phase IV | rekrutiert |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Phase III | rekrutiert |
| Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Ge | Phase III | rekrutiert |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase III | rekrutiert |
| Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in A | Phase III | rekrutiert |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase III | rekrutiert |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial | Phase II / Phase III | rekrutiert |
| Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Withou | — | rekrutiert |
| Register Schweres Asthma - German Asthma Net e.V. | — | rekrutiert |
| Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Ac | — | rekrutiert |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for P | Phase III | rekrutiert |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Inve | Phase II / Phase III | rekrutiert |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants W | Phase I / Phase II | rekrutiert |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-sm | Phase II / Phase III | rekrutiert |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated E | Phase III | rekrutiert |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in | Phase III | rekrutiert |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HE | Phase III | rekrutiert |
| The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in I | Phase III | rekrutiert |
| Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Partic | Phase II | rekrutiert |